Patents by Inventor Daotai Nie

Daotai Nie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FC101 and analogs as a method of treatment for cancer
    Patent number: 7078433
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: July 18, 2006
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • FC101 and analogs as a method of treatment for cancer
    Publication number: 20040092580
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 13, 2004
    Applicant: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • FC101 as a method of treatment for cancer
    Patent number: 6660765
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: December 9, 2003
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • FC101 as a method of treatment for cancer
    Publication number: 20030083370
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Application
    Filed: August 2, 2002
    Publication date: May 1, 2003
    Inventors: Roy E. Wuthier, Daotai Nie
  • Use of an angiogenesis inhibitor as a lead compound in drug development
    Publication number: 20010011100
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Application
    Filed: March 29, 2001
    Publication date: August 2, 2001
    Inventors: Roy E. Wuthier, Daotai Nie
  • Angiogenesis inhibitor for the treatment of endothelial cell proliferation
    Patent number: 6225340
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: May 1, 2001
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • Angiogenesis inhibitor for the treatment of cancer
    Patent number: 5932611
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: August 3, 1999
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie